Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0304822 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift PLOS ONE, 2024. Verfasst von Christopher F Bell und 12 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, United States of America. Hauptthemen laut MEDLINE: Hospitalization, Antibodies, Monoclonal, Humanized, COVID-19, Electronic Health Records. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: GSK and Vir Biotechnology, Inc.
Abstract (Originalsprache)
Background
To describe outcomes of high-risk patients with coronavirus disease 2019 (COVID-19) treated with sotrovimab, other monoclonal antibodies (mAbs), or antivirals, and patients who did not receive early COVID-19 treatment. We also evaluate the comparative effectiveness of sotrovimab versus no treatment in preventing severe clinical outcomes.
Methods
This observational retrospective cohort study analyzed Mayo Clinic electronic health records. Non-hospitalized adult patients diagnosed with COVID-19 from May 26, 2021 and April 23, 2022 and at high risk of COVID-19 progression were eligible. The primary outcome was 29-day all-cause hospitalization and/or death. Outcomes were described for patients treated with sotrovimab, other mAbs, or antivirals, and eligible but untreated patients, and compared between sotrovimab-treated and propensity score (PS)-matched untreated cohorts.
Results
We included 35,485 patients (sotrovimab, 1369; other mAbs, 6488; antivirals, 133; high-risk untreated, 27,495). A low proportion of patients treated with sotrovimab (n = 33/1369, 2.4%), other mAbs (n = 147/6488, 2.3%), or antivirals (n = 2/133, 1.5%) experienced all-cause hospitalization or death. Among high-risk untreated patients, the percentage of all-cause hospitalization or death was 3.3% (n = 910/27,495). In the PS-matched analysis, 2.5% (n = 21/854) of sotrovimab-treated patients experienced all-cause hospitalization and/or death versus 2.8% (n = 48/1708) of untreated patients (difference, –0.4%; p = 0.66). Significantly fewer sotrovimab-treated patients required intensive care unit admission (0.5% vs 1.8%; difference, –1.3%; p = 0.002) or respiratory support (3.5% vs 8.7%; difference, –5.2%; p < 0.001).
Conclusions
There was no significant difference in the proportion of sotrovimab-treated and PS-matched untreated patients experiencing 29-day all-cause hospitalization or mortality, although significantly fewer sotrovimab-treated patients required intensive care unit admission or respiratory support.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- GSK, Durham, North Carolina, United States of America.
- GSK, Brentford, United Kingdom.
- nference, Cambridge, Massachusetts, United States of America.
- Mayo Clinic, Rochester, Minnesota, United States of America.
ORCID-Profile: Christopher F Bell, Katherine Carlson, John C O'Horo
Förderung
- GSK and Vir Biotechnology, Inc
Zitieren
APA
Bell, C. F., Gibbons, D. C., Drysdale, M., Birch, H. J., Lloyd, E. J., Patel, V., Carpenter, C., Carlson, K., Calay, E. S., Puranik, A., Wagner, T. E., O'Horo, J. C., & Razonable, R. R. (2024). Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PLOS ONE. https://doi.org/10.1371/journal.pone.0304822
Vancouver
Bell CF, Gibbons DC, Drysdale M, Birch HJ, Lloyd EJ, Patel V, et al. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records. PLOS ONE. 2024. doi:10.1371/journal.pone.0304822
BibTeX
@article{Bell2024,
author = {Bell, Christopher F and Gibbons, Daniel C and Drysdale, Myriam and Birch, Helen J and Lloyd, Emily J and Patel, Vishal and Carpenter, Corinne and Carlson, Katherine and Calay, Ediz S and Puranik, Arjun and Wagner, Tyler E and O'Horo, John C and Razonable, Raymund R},
title = {Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0304822}
}
EUVIMED